We evaluated whether matrix metalloproteinases (MMPs) 2 and 9, their inhibitors, markers for fibrinolysis, and thrombin activation are associated with diameter and growth of abdominal aortic aneurysms (AAAs). Material and Methods: Matrix metalloproteinases 2 and 9, tissue inhibitor of MMPs (TIMP-1), serpine-1, tPa-serpine-1, and activated protein C— protein C inhibitor (APC-PCI) complex were analyzed in 353 patients with AAA grouped according to AAA size, and 219 gender- and age-matched healthy individuals. Follow-up of AAA growth for up to 7 years was possible in 178 of 353 patients. Results: At baseline, all groups of patients with AAA showed lower levels of MMP-2 and -9, and higher levels of TIMP-1, serpine-1, and t-Pa-serpine-1 than controls. Matrix metalloproteinase 2 correlated inversely and APC-PCI complex correlated directly with AAA diameter. We found no correlations between markers for proteolysis, fibrinolysis, coagulation, and yearly AAA growth. Conclusion: Matrix metalloproteinase 2 is lower and APC-PCI higher in patients with larger AAA, but the relevance of the markers for AAA growth is far from clarified.
Raffetto JD, Khalil RAMatrix metalloproteinases and their inhibitors in vascular remodeling and vascular disease. Biochem Pharmacol. 2008 ;75:346-359.
2.
Crowther M., Goodall S., Jones JL, Bell PR, Thompson MMLocalization of matrix metalloproteinase 2 within the aneurysmal and normal aortic wall. Br J Surg. 2000;87(10):1391-1400.
3.
Petersen E., Gineitis A., Wagberg F., Angquist KAActivity of matrix metalloproteinase-2 and -9 in abdominal aortic aneurysms . Relation to size and rupture. Eur J Vasc Endovasc Surg. 2000; 20(5):457-461.
4.
Davis V., Persidskaia R., Baca-Regen L., et al. Matrix metalloproteinase-2 production and its binding to the matrix are increased in abdominal aortic aneurysms. Arterioscler Thromb Vasc Biol. 1998;18(10):1625-1633.
5.
Sakalihasan N., Delvenne P., Nusgens BV, Limet R., Lapiere CMActivated forms of MMP2 and MMP9 in abdominal aortic aneurysms. J Vasc Surg . 1996;24(1):127-133.
Wassef M., Baxter BT, Chisholm RL, et al. Pathogenesis of abdominal aortic aneurysms: a multidisciplinary research program supported by the National Heart, Lung, and Blood Institute . J Vasc Surg. 2001;34(4):730-738.
8.
Lindholt JS, Jörgensen B., Fasting H., Henneberg EWPlasma levels of plasmin-antiplasmin-complexes are predictive for small abdominal aortic aneurysms expanding to operation-recommendable sizes . J Vasc Surg. 2001;34(4):611-615.
9.
Smith FB, Lee AJ, Rumley A., Fowkes FGR, Lowe GDO.Tissue plasminogen activator, plasminogen activator inhibitor and risk of peripheral arterial disease. Atherosclerosis. 1995;115(1): 35-43.
10.
Wanhainen A. , Nilsson TK, Bergqvist D., Boman K., Björck M.Elevated tissue plasminogen activator in patients with screening-detected abdominal aortic aneurysm. J Vasc Surg. 2007;45(6):1109-1113.
11.
Yamazumi K. , Ojiro M., Okumura H., Aikou T.An activated state of blood coagulation and fibrinolysis in patients with abdominal aortic aneurysm . Am J Surg. 1998;175(4):297-301.
12.
Strandberg K., Kjellberg M., Knebel R., Lilja H., Stenflo J. A sensitive immunochemical assay for measuring the concentration of the activated protein C-protein C inhibitor complex in plasma: use of a catcher antibody specific for the complexed/cleaved form of the inhibitor. Thromb Haemost. 2001 ;86(2):604-610.
13.
Kölbel T., Strandberg K., Mattiasson I., Stenflo J., Lindblad B.Activated protein C-protein C inhibitor complex: a new biological marker for aortic aneurysms . J Vasc Surg . 2006;43(5):935-939.
14.
Schouten O. , van Laanen JH, Boersma E., Vidakovic R., Feringa HH, Dunkelgrun M.Statins are associated with a reduced infrarenal abdominal aortic aneurysm growth. Eur J Vasc Endovasc Surg . 2006;32(1):21-26.
15.
Flondell-Sité D., Lindblad B., Kölbel T., Gottsäter A.Cytokines and systemic biomarkers are related to the size of abdominal aortic aneurysms . Cytokine. 2009;46(2):211-215.
16.
Flondell-Sité D., Lindblad B., Gottsäter A.High levels of endothelin (ET)-1 and aneurysm diameter independently predict growth of stable abdominal aortic aneurysms. Angiology2009; Aug 18 [Epub ahead of print].
17.
Nilsson P., Berglund G.Prevention of cardiovascular disease and diabetes: lessons from the Malmo Preventive Project. J Intern Med. 2000 ;248(6):455-462.
18.
Strandberg K., Svensson A., Stenflo J.Stabilyte tubes that contain strongly acidic citrate prevent in vitro complex formation between activated protein C and protein C inhibitor. Thromb Haemost . 2003;89(5):947-949.
19.
Papalambros E., Sigala F., Georgopoulos S., et al. Immunohistochemical expression of metalloproteinases MMP-2 and MMP-9 in abdominal aortic aneurysms: correlation with symptoms and aortic diameter. Int J Mol Med . 2003;12(6):965-968.
20.
McMillan WD , Pearce WHIncreased plasma levels of metalloproteinase-9 are associated with abdominal aortic aneurysms. J Vasc Surg . 1999;29(1):122-127.
21.
Wilson WRW , Anderton M., Choke EC, Dawson J., Loftus IM, Thompson MMElevated Plasma MMP1 and MMP9 are associated with abdominal aortic aneurysm rupture. Eur J Vasc Endovasc Surg. 2008;35(5):580-584.
22.
Smith L., Marenghi AS, Capper SJDetermination of Species Cross-Reactivity Using MMP-2 Activity Assay and Correlation With ELISA and Gelatin Zymography. Amersham Place, England: Amersham Biosciences UK Ltd. An S 1371/99/06 p1-2.
23.
Lindholt JS , Vammen S., Fasting H., Henneberg EW, Heickendorff L.The plasma level of matrix metalloproteinase 9 may predict the natural history of small abdominal aortic aneurysms. A preliminary study. Eur J Vasc Endovasc Surg. 2000; 20(3):281-285.
24.
Tamarina NA , McMillan WD, Shively VP, Pearce WHExpression of matrix metalloproteinases and their inhibitors in aneurysms and normal aorta . Surgery. 1997;122(2):264-271.
25.
Defawe OD, Colige A., Lambert CA, et al. TIMP-2 and PAI-1 mRNA levels are lower in aneurysmal as compared to athero-occlusive abdominal aortas. Cardiovasc Res. 2003;60(1): 205-213.
26.
Hinterseher I., Krex D., Kuhlisch E., et al. Tissue inhibitor of metalloproteinase-1 (TIMP-1) polymorphisms in a Caucasian population with abdominal aortic aneurysm . World J Surg. 2007;31(11):2248-2254.
27.
Golledge J. , Karan M., Moran CS, et al. Reduced expansion rate of abdominal aortic aneurysms in patients with diabetes may be related to aberrant monocyte-matrix interactions. Eur Heart J. 2008;29(5):665-672.
28.
Hovsepian DM , Ziporin SJ, Sakurai MK, Lee JK, Curci JA, Thompson RWElevated plasma levels of matrix metalloproteinase-9 in patients with abdominal aortic aneurysms: a circulating marker of degenerative aneurysm disease. J Vasc Interv Radiol. 2000 ;11(10):1345-1352.
29.
Eugster T., Huber A., Obeid T., Schwegler I., Gurke L., Stierli P.Aminoterminal propeptide of type III procollagen and matrix metalloproteinases-2 and -9 failed to serve as serum markers for abdominal aortic aneurysm. Eur J Vasc Endovasc Surg. 2005; 29(4):378-382.
30.
Houard X., Rouzet F., Touat Z., et al. Topology of the fibrinolytic system within the mural thrombus of human abdominal aortic aneurysms. J Pathol. 2007;212(1):20-28.
31.
Lindholt JSActivators of plasminogen and the progression of small abdominal aortic aneurysms. Ann N Y Acad Sci. 2006; 1085:139-150.
